R&D | Cutting-edge science and innovative research

News

Ultragenyx to slash costs after Angelman trial failure

Ultragenyx's therapy for the rare genetic disorder Angelman syndrome, apazunersen, has flunked a late-stage trial, crashing its share price.

News

Hutchmed rises on $1.3bn KRAS licensing deal with GSK

GSK has paid Hutchmed $110m upfront for rights to a preclinical KRAS and EGFR-directed drug with potential in colorectal, pancreatic, and lung cancer.

R&D

Back to basics: X-ray inspection in pharmaceutical and medic...

In pharma manufacturing, x-ray inspection supports a range of quality control processes.

News

Akeso's ivonescimab extends survival in PD-L1+ lung cancer

Akeso's PD-1xVEGF drug ivonescimab improves survival in another late-stage Chinese trial, ahead of a key international study readout later this year.

News

Boehringer signs AI drug discovery deal with Owkin

Boehringer Ingelheim has joined Sanofi and AstraZeneca in signing up to deploy Owkin's AI platform K Pro in its drug discovery operations.

News

Moderna shows in vivo CAR-T hand in R&D update

At its latest R&D update, Moderna revealed a move into the pioneering in vivo CAR-T category, adding another treatment class to its R&D capabilities.

News

Merck buys life sciences firm Bio-Techne in $11.3bn deal

Merck KGaA is poised to increase the size of its life sciences business with an $11.3 billion deal to acquire rival Bio-techne.

News

Hub-and-spoke firm Osanni raises $190m, and other financings

Our latest roundup of venture capital financings in the biotech sector includes rounds for Osanni Bio, Bionyra, Serapha, Nura Bio, and Oblenio.

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

R&D

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

Ultragenyx to slash costs after Angelman trial failure

Ultragenyx's therapy for the rare genetic disorder Angelman syndrome, apazunersen, has flunked a late-stage trial, crashing its share price.

News

Hutchmed rises on $1.3bn KRAS licensing deal with GSK

GSK has paid Hutchmed $110m upfront for rights to a preclinical KRAS and EGFR-directed drug with potential in colorectal, pancreatic, and lung cancer.

Press Releases

Partner Content

The Evolution Summit Announces September 2026 Program for Cl...

Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.

Press Releases

Partner Content

Navigating Change: Key Industry Insights at PHARMAP 2026

PHARMAP returns in 2027 in Berlin, Germany, with Bayer as the Host Sponsor

Views & Analysis

R&D

Back to basics: X-ray inspection in pharmaceutical and medic...

In pharma manufacturing, x-ray inspection supports a range of quality control processes.

R&D

Decarbonising respiratory care requires a new kind of generi...

Generics manufacturers have long played a critical role in supporting the sustainability of the NHS, delivering affordable medicines at scale, expanding patient access, and helping healthca

R&D

Why the future of eSource starts with the research site

Capturing data digitally at source can significantly reduce the workflow for sites, yet, implementing it across studies has been rather unattainable.

Deep Dive

R&D

Cancer misinformation is a trust problem, not just an inform...

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

Podcasts

R&D

pharmaphorum podcast Episode 272, Dr Harpreet Singh, Precision for Medicine

Understanding Operation Trialblazer, with Dr Harpreet Singh

Dr Harpreet Singh, CMO at Precision for Medicine, brings both an insider and outsider perspective to discussing Operation TRIALBLAZER.

R&D

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

R&D

CAMP4 on a new class of ASO in gene under expression

CAMP4 Therapeutics CFO Kelly Gold discusses developments in antisense oligonucleotides and CAMP4’s CMP-002 study

Video

R&D

two healthcare professionals looking at chart

Sponsored

Decentralisation by design: Bringing the trial closer withou...

In the third episode of the IQVIA-sponsored PSCS leadership video series, Sinead Callinan, Head of Patient Centred Delivery, discusses DCTs.

R&D

Sponsored

Patient population first: the strategy behind country decisi...

R&D

Sponsored

IQVIA on reducing complexity and workload for clinical trial...

White Papers

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.